Buckhead Capital Management LLC Buys 15 Shares of Eli Lilly and Company (NYSE:LLY)

Buckhead Capital Management LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 0.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 2,104 shares of the company’s stock after buying an additional 15 shares during the period. Buckhead Capital Management LLC’s holdings in Eli Lilly and Company were worth $1,226,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Eli Lilly and Company by 0.9% in the 3rd quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the last quarter. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Northern Trust Corp grew its stake in Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock worth $5,456,314,000 after purchasing an additional 355,317 shares during the period. International Assets Investment Management LLC grew its stake in Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock worth $42,802,530,000 after purchasing an additional 7,330,815 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Eli Lilly and Company by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock worth $2,382,339,000 after purchasing an additional 88,016 shares during the period. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock traded down $4.35 during trading on Wednesday, reaching $776.75. 2,762,706 shares of the stock traded hands, compared to its average volume of 3,067,439. The company has a market capitalization of $738.04 billion, a price-to-earnings ratio of 133.47, a P/E/G ratio of 1.61 and a beta of 0.34. The business has a fifty day simple moving average of $761.41 and a two-hundred day simple moving average of $669.21. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73. Eli Lilly and Company has a 52-week low of $399.26 and a 52-week high of $800.78.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion during the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.62 earnings per share. Sell-side analysts expect that Eli Lilly and Company will post 12.51 EPS for the current year.

Wall Street Analyst Weigh In

LLY has been the subject of several recent analyst reports. The Goldman Sachs Group raised their target price on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research note on Thursday, April 11th. Truist Financial raised their price objective on Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. Wells Fargo & Company raised their price objective on Eli Lilly and Company from $700.00 to $825.00 and gave the company an “overweight” rating in a research note on Tuesday, February 6th. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Finally, Citigroup raised their price objective on Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $742.95.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.